Search Results - "Rusen, L."

Effect of late prophylaxis in hemophilia on joint status: a randomized trial by Manco‐Johnson, M. J., Lundin, B., Funk, S., Peterfy, C., Raunig, D., Werk, M., Kempton, C. L., Reding, M. T., Goranov, S., Gercheva, L., Rusen, L., Uscatescu, V., Pierdominici, M., Engelen, S., Pocoski, J., Walker, D., Hong, W.

“…Essentials High‐quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3‐year randomized clinical trial of…”
Get full text

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) by Manco‐Johnson, M. J., Kempton, C. L., Reding, M. T., Lissitchkov, T., Goranov, S., Gercheva, L., Rusen, L., Ghinea, M., Uscatescu, V., Rescia, V., Hong, W.

“…Summary Background The benefits of routine prophylaxis vs. on‐demand treatment with factor VIII products have not been evaluated in controlled clinical trials…”
Get full text

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors by KONKLE, B. A., EBBESEN, L. S., ERHARDTSEN, E., BIANCO, R. P., LISSITCHKOV, T., RUSEN, L., SERBAN, M. A.

“…Background: Hemophilic patients with factor VIII (FVIII) and FIX inhibitors suffer from frequent bleeding episodes and reduced quality of life. Objectives: To…”
Get full text

Temperature responsive functional polymeric thin films obtained by matrix assisted pulsed laser evaporation for cells attachment–detachment study by Rusen, L., Dinca, V., Mitu, B., Mustaciosu, C., Dinescu, M.

“…•PNIPAAm thermo responsive films were obtained by MAPLE.•PNIPAAm films were utilized in L929 cell adhesion and detachment studies.•Confirmation of the polymer…”
Get full text

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A by Lissitchkov, T., Rusen, L., Georgiev, P., Windyga, J., Klamroth, R., Gercheva, L., Nemes, L., Tiede, A., Bichler, J., Knaub, S., Belyanskaya, L., Walter, O., Pasi, K. J.

“…Introduction Nuwiq® (human‐cl rhFVIII) is a 4th generation recombinant human FVIII, without chemical modification or protein fusion, produced in a human…”
Get full text

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A by Dargaud, Y., Negrier, C., Rusen, L., Windyga, J., Georgiev, P., Bichler, J., Solomon, C., Knaub, S., Lissitchkov, T., Klamroth, R.

“…Introduction For individuals with haemophilia A, prophylaxis with factor VIII (FVIII) is typically directed towards trough activity >1 IU/dL; however, some…”
Get full text

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) by Kavakli, K., Yang, R., Rusen, L., Beckmann, H., Tseneklidou‐Stoeter, D., Maas Enriquez, M., Yang, Renchi, Zhao, Yongqiang, Sun, Jing, Wang, Xuefeng, Wu, Depei, Hlusi, Antonin, Fukutake, Katsuyuki, Hanabusa, Hideji, Fujii, Teruhisa, Ramírez, Oscar Pérez, Alvarado, Blanca Salazar, Serban, Margit, Rusen, Luminita, Uscatescu, Valentina, Truica, Cristina, Kostic, Gordana, Konstantinidis, Nada, Igrutinovic, Zoran, Perina, Farida, Andreeva, Tatiana, Kavakli, Kaan, Antmen, Bulent, Sasmaz, Ilgen, Kupesiz, Alphan, Yesilipek, Mehmet Akif, Peng, Ching‐Tien, French, James, Escobar, Miguel, Mahlangu, Johnny, Pool, Roger

“…Summary Background BAY 81‐8973 is a new full‐length human recombinant factor VIII product manufactured with technologies to improve consistency in…”
Get full text

Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects by Valentino, L. A., Rusen, L., Elezovic, I., Smith, L. M., Korth-Bradley, J. M., Rendo, P.

“…Summary Few randomized studies have reported on the use of factor IX (FIX) for secondary prophylaxis in haemophilia B patients. This study aimed to evaluate…”
Get full text

Novel degradable biointerfacing nanocomposite coatings for modulating the osteoblast response by Rusen, L., Brajnicov, S., Neacsu, P., Marascu, V., Bonciu, A., Dinescu, M., Dinca, V., Cimpean, A.

“…Design and functionalization strategies for bio-functional coatings based on biodegradable and biocompatible materials intended to be employed for targeting…”
Get full text

Antireflective coatings with high damage threshold prepared by laser ablation by Filipescu, M., Palla-Papavlu, A., Bercea, A., Rusen, L., Cernaianu, M. O., Ion, V., Calugar, A., Nistor, L. C., Dinescu, M.

“…Latest developments in the field of high power ultra-short pulse lasers have led to intensive studies dedicated to the fabrication possibility of new…”
Get full text

Excimer laser texturing of natural composite polymer surfaces for studying cell-to-substrate specific response by Dinca, V., Alloncle, P., Delaporte, P., Ion, V., Rusen, L., Filipescu, M., Mustaciosu, C., Luculescu, C., Dinescu, M.

“…•Roughness gradients are obtained in one step by applying single laser pulses and sample tilting.•BSA protein and cell dependence behavior onto gradient…”
Get full text

Characterization of ethylcellulose and hydroxypropyl methylcellulose thin films deposited by matrix-assisted pulsed laser evaporation by Palla-Papavlu, A., Rusen, L., Dinca, V., Filipescu, M., Lippert, T., Dinescu, M.

“…•Ethylcellulose (EC) was deposited by matrix-assisted pulsed laser evaporation MAPLE.•Hydroxypropyl methylcellulose (HPMC) was deposited by MAPLE.•Chemical…”
Get full text

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial by Ljung, R., Kenet, G., Mancuso, M. E., Kaleva, V., Rusen, L., Tseneklidou-Stoeter, D., Michaels, L. A., Shah, A., Hong, W., Maas Enriquez, M.

“…Introduction BAY 81‐8973, a full‐length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino…”
Get full text

Protein-resistant polymer coatings obtained by matrix assisted pulsed laser evaporation by Rusen, L., Mustaciosu, C., Mitu, B., Filipescu, M., Dinescu, M., Dinca, V.

“…► Protein-resistant copolymer coatings are obtained by MAPLE. ► The depositions parameters are correlated to surface characteristics. ► Hydrophobic coating…”
Get full text

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies by Rusen, L., Kavakli, K., Korth‐Bradley, J., Huard, F., Rendo, P., Fuiman, J., Baumann, J. A., Smith, L., Alvey, C., Rupon, J.

“…Introduction The pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF‐CC) have been demonstrated in haemophilia A patients aged ≥6 years. Aim…”
Get full text

Tailored topography control of biopolymer surfaces by ultrafast lasers for cell–substrate studies by Rusen, L., Cazan, M., Mustaciosu, C., Filipescu, M., Sandel, S., Zamfirescu, M., Dinca, V., Dinescu, M.

“…•Bubble, fingertip, sponge like structures can be obtained by fs laser irradiation.•The structures characteristics depend on laser wavelength, fluence and…”
Get full text

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B by Windyga, J., Lissitchkov, T., Stasyshyn, O., Mamonov, V., Rusen, L., Lamas, J. L., Oh, M.-S., Chapman, M., Fritsch, S., Pavlova, B. G., Wong, W.-Y., Abbuehl, B. E.

“…Summary BAX326 is a recombinant factor IX (rFIX; nonacog gamma) manufactured without the addition of any materials of human or animal origin, and with two…”
Get full text

Polyethyleneimine patterns obtained by laser-transfer assisted by a Dynamic Release Layer onto Themanox soft substrates for cell adhesion study by Dinca, V., Mattle, T., Palla Papavlu, A., Rusen, L., Luculescu, C., Lippert, T., Dinescu, M.

“…► Polymer pixels were printed by LIFT onto soft flexible and stiff substrates. ► The surface pixel morphology depends on fluence and substrate type. ► The…”
Get full text

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326) by Solano Trujillo, M. H., Stasyshyn, O., Rusen, L., Serban, M., Lamas, J. L., Perina, F. G., Urasinski, T., Oh, M., Knowlton, W. B., Valenta-Singer, B., Pavlova, B. G., Abbuehl, B.

“…Summary The ability to switch between coagulation factors safely is of common interest to haemophilia patients and treating physicians. This is the first…”
Get full text

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial by Urasinski, T., Stasyshyn, O., Andreeva, T., Rusen, L., Perina, F. G., Oh, M. S., Chapman, M., Pavlova, B. G., Valenta-Singer, B., Abbuehl, B. E.

“…Summary A newly developed recombinant factor IX (BAX3261) was investigated for prophylactic use in paediatric patients aged <12 years with severe (FIX level…”
Get full text